Breaking points on a progressive ratio schedule reinforced by intravenous apomorphine increase daily following 6-hydroxydopamine lesions of the nucleus accumbens

Pharmacology, Biochemistry, and Behavior
D C Roberts

Abstract

It has been shown previously that 6-hydroxydopamine (6-OHDA)-induced lesions of the nucleus accumbens cause extinction of cocaine self-administration behavior, yet fail to affect the rate of apomorphine self-administration on a Fixed Ratio 1 schedule of reinforcement. Since the dopamine (DA) receptors in this nucleus should become supersensitive, and since these receptors are thought to mediate the reinforcing effects of apomorphine, then some change in apomorphine self-administration would be expected. We have therefore reinvestigated the effect of 6-OHDA lesions on apomorphine self-administration using a progressive ratio schedule of reinforcement. Rats were trained to self-administer apomorphine (0.033 mg/inj, IV) on a schedule in which the response requirements increased after each reinforcement. The breaking point was defined as the final ratio completed during each daily session. Sham lesions had no effect on the breaking points, and a steady increase in the breaking point was observed in the 6-OHDA-lesioned animals which may parallel the development of DA receptor supersensitivity.

References

Jul 19, 1978·Psychopharmacology·R A Yokel, R A Wise
Nov 1, 1978·Pharmacology, Biochemistry, and Behavior·J A BedfordM C Wilson
Jun 1, 1977·Pharmacology, Biochemistry, and Behavior·D C RobertsH C Fibiger
May 1, 1978·Pharmacology, Biochemistry, and Behavior·D M Jacobowitz, J S Richardson
May 1, 1974·Pharmacology, Biochemistry, and Behavior·B L BaxterR A Scerni
Jan 1, 1981·Psychopharmacology·M E Risner, D L Silcox
May 1, 1980·Pharmacology, Biochemistry, and Behavior·D C RobertsH C Fibiger

❮ Previous
Next ❯

Citations

Jan 1, 1993·Psychopharmacology·A MarkouG F Koob
Jul 1, 1995·Psychopharmacology·A SmithD C Roberts
Mar 18, 2005·Psychopharmacology·Mathew T Martin-Iverson, Kirsten N Stevenson
Jul 1, 1991·Pharmacology, Biochemistry, and Behavior·L E Markert, D C Roberts
Jul 1, 1993·Pharmacology, Biochemistry, and Behavior·R Y DepoortereM W Emmett-Oglesby
Jul 1, 1997·Pharmacology, Biochemistry, and Behavior·B A RochaR Hen
Jul 1, 1997·Pharmacology, Biochemistry, and Behavior·J M Arnold, D C Roberts
Oct 6, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Zheng-Xiong XiEliot L Gardner
Jun 28, 1992·Annals of the New York Academy of Sciences·L StinusM Le Moal
Mar 11, 2011·The Journal of Pharmacology and Experimental Therapeutics·James J CortrightPaul Vezina
Feb 11, 2014·Experimental Neurology·Samara A M BobzeanLinda I Perrotti
Jun 28, 2015·Neuroscience and Biobehavioral Reviews·Florence AllainAnne-Noël Samaha
Sep 25, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·David C S RobertsYu Liu
Oct 19, 2006·Physiology & Behavior·Dianne P FiglewiczJeffrey W Grimm
Sep 27, 2005·Pharmacology & Therapeutics·Charles P O'Brien, Eliot L Gardner
Sep 4, 2012·Neurobiology of Disease·Michel EngelnPierre-Olivier Fernagut
Jul 16, 2019·Psychiatry and Clinical Neurosciences·Kenji F Tanaka, Takuya Hamaguchi
Apr 2, 2003·Psychopharmacology·David C S RobertsHuw M L Davies
Jun 1, 1990·Natural Product Reports·K W Bentley

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.